Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 1.09 Delayed Data As of Sep 20 |  +0.01 / +0.93%Today’s Change | 0.80 Today|||52-Week Range 1.42 | +18.48% Year-to-Date |
| Previous close | 1.08 |
| Today’s open | 1.07 |
| Day’s range | 1.06 - 1.09 |
| Volume | 147,540 |
| Average volume (3 months) | 479,519 |
| Market cap | $112.4M |
| Dividend yield | -- |
| Earnings growth (last year) | -0.36% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -25.00% |
| Revenue growth (last year) | -- |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | 1.76 |
| Today’s change | Today’s % change | |
|---|---|---|
| CPIXCumberland Pharmaceu... | -0.03 | -0.42% |
| --EcoGreen Internation... | +0.02 | +13.29% |
| ORMPOramed Pharmaceutica... | -0.09 | -0.94% |
| AGRXAgile Therapeutics I... | +0.10 | +2.75% |
| Next reporting date | November 21, 2017 |
| EPS forecast (this quarter) | -$0.05 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$15.9M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chief Executive Officer & Head-Investor Relations Philip Adam Serlin |
Chief Financial Officer Mali Zeevi |
Corporate headquarters Modi'in, Tel Aviv |
